Janick Weberpals

Janick Weberpals

Auto-generated profile, based on publicly available information

Janick Weberpals

Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2016 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
JWJanick Weberpals
Janick Weberpals
LJLina Jansen
Lina Jansen
PCPrudence Carr
Prudence Carr
MHMichael Hoffmeister
Michael Hoffmeister
HBHermann Brenner
Hermann Brenner

1 September 2017 in European Journal of Epidemiology
Verified
Journal Article
Closed access
PDF file
JWJanick Weberpals
Janick Weberpals
LJLina Jansen
Lina Jansen
MHMyrthe P. P. van Herk-Sukel
Myrthe P. P. van Herk-Sukel
JKJosephina G. Kuiper
Josephina G. Kuiper
MAMieke J. Aarts
Mieke J. Aarts
HBHermann Brenner
Hermann Brenner

6 June 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JWJanick Weberpals
Janick Weberpals
LJLina Jansen
Lina Jansen
WHWalter E. Haefeli
Walter E. Haefeli
MHMichael Hoffmeister
Michael Hoffmeister
MWMartin Wolkewitz
Martin Wolkewitz
HBHermann Brenner
Hermann Brenner
Beta-blockers have been associated with decreased cancer mortality. However, evidence for lung cancer is sparse and reported beneficial effects might be based on biased analyses. In this so far largest study we investigated the association between β-blocker use and lung cancer survival. Therefore, patients with a lung cancer diagnosis between April 1998 and December 2011 were selected from a database linkage of the Netherlands Cancer Registry and the PHARMO Database Network. After matching eligible patients on the propensity score, adjusted hazard ratios (HRs) and corresponding 95% confidence intervals (CI) were calculated using Cox proportional hazards regression to investigate the association between pre-diagnostic and time-dependent β-blocker use and overall survival. Duration and dose-response analyses and stratified analyses by β-blocker type, histological subgroups and stage were conducted. Of 3,340 eligible lung cancer patients, 1437 (43%) took β-blockers four months prior to diagnosis. Pre-diagnostic β-blocker use was not associated with overall survival (HR 1.00 (0.92–1.08)) in the adjusted model. Time-dependent post-diagnostic analysis showed similar results with a HR of 1.03 (0.94–1.11). Trend analyses showed no association for cumulative dose (HR 0.99 (0.97–1.02)) and cumulative duration (HR 1.00 (0.96–1.05)). In conclusion, β-blocker use is not associated with reduced mortality among lung cancer patients.

4 January 2024 in JAMIA Open
Verified
Journal Article
Open access
PDF file
JWJanick Weberpals
Janick Weberpals
SRSudha R Raman
Sudha R Raman
PSPamela A Shaw
Pamela A Shaw
HLHana Lee
Hana Lee
BHBradley G Hammill
Bradley G Hammill
RDRishi J Desai
Rishi J Desai
Objectives: Partially observed confounder data pose a major challenge in statistical analyses aimed to inform causal inference using electronic health records (EHRs). While analytic approaches such as imputation are available, assumptions on underlying missingness patterns and mechanisms must be verified. We aimed to develop a toolkit to streamline missing data diagnostics to guide choice of analytic approaches based on meeting necessary assumptions. Materials and methods: We developed the smdi (structural missing data investigations) R package based on results of a previous simulation study which considered structural assumptions of common missing data mechanisms in EHR. Results: smdi enables users to run principled missing data investigations on partially observed confounders and implement functions to visualize, describe, and infer potential missingness patterns and mechanisms based on observed data. Conclusions: The smdi R package is freely available on CRAN and can provide valuable insights into underlying missingness patterns and mechanisms and thereby help improve the robustness of real-world evidence studies.

24 July 2025 in NEJM AI
Verified
Journal Article
Closed access
JWJanick Weberpals
Janick Weberpals
SFStefan Feuerriegel
Stefan Feuerriegel
MSMihaela van der Schaar
Mihaela van der Schaar
KKKenneth L. Kehl
Kenneth L. Kehl

26 August 2020 in Cancers
Verified
Journal Article
Open access
PDF file
LJLina Jansen
Lina Jansen
BHBernd Holleczek
Bernd Holleczek
KKKlaus Kraywinkel
Klaus Kraywinkel
JWJanick Weberpals
Janick Weberpals
CSChloé Charlotte Schröder
Chloé Charlotte Schröder
HBHermann Brenner
Hermann Brenner
Background: Breast cancer treatment has changed tremendously over the last decades. In addition, the use of mammography screening for early detection has increased strongly. To evaluate the impact of these developments, long-term trends in incidence, mortality, stage distribution and survival were investigated for Germany and the United States (US). Methods: Using population-based cancer registry data, long-term incidence and mortality trends (1975–2015), shifts in stage distributions (1998–2015), and trends in five-year relative survival (1979–2015) were estimated. Additionally, trends in five-year relative survival after standardization for stage were explored (2004–2015). Results: Age-standardized breast cancer incidence rates were much higher in the US than in Germany in all periods, whereas age-standardized mortality began to lower in the US from the 1990s on. The largest and increasing differences were observed for patients aged 70+ years with a 19% lower incidence but 45% higher mortality in Germany in 2015. For this age group, large differences in stage distributions were observed, with 29% (Germany) compared to 15% (US) stage III and IV patients. Age-standardized five-year relative survival increased strongly between 1979–1983 and 2013–2015 in Germany (+17% units) and the US (+19% units) but was 9% units lower in German patients aged 70+ years in 2013–2015. This difference was entirely explained by differences in stage distributions. Conclusions: Overall, our results are in line with a later uptake and less extensive utilization of mammography screening in Germany. Further studies and efforts are highly needed to further explore and overcome the increased breast cancer mortality among elderly women in Germany.